Plasma Citrulline in Preterm With NEC | Clinical Trial

Key information

Conditions

NEC Citrulline

Age range

1 day–30 day

Sex eligibility

All sexes

Study type

Observational

Primary location

AinShams University

Cairo, Egypt

About this study

Introduction

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

preterm neonates < 35 weeks Preterm neonates< 2kg Preterm neonates diagnosed with necrotizing enterocolitis

Exclusion criteria

renal dysfunction Inborn error of metabolism Congenital malformation

Treatment and study plan

Primary outcomes

plasma citrulline as a marker of Necrotizing enterocolitis diagnosis

Time frame: 1 Year

Compare plasma citrulline in NEC and comparing it with properly matched healthy neonates

Secondary outcomes

Citrulline as a marker of intestinal recovery

Time frame: 1 year

Follow up plasma citrulline level after initiation of feeding

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Acronym: NEC

Important dates

Study start: 2019
Primary completion: 2020
Study completion: 2020
First posted: Mar 18, 2020
Registry last updated: Mar 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed